Search
Serina Therapeutics Inc
SERAdd to Watchlist
1.945USD
+0.005+0.26%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
28.80MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-01The current earnings forecast score of Serina Therapeutics Inc is 8.00, ranking 166 out of 387 in the Biotechnology & Medical Research industry. The average price target is 13.00, with a high of 15.00 and a low of 11.00.
Analyst Rating
Based on
2
analysts
Strong Buy
Current Rating
11.333
Target Price
+484.19%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
562
Total
5
Median
6
Average
Company name
Ratings
Analysts
Serina Therapeutics Inc
SER
2
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
113
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Serina Therapeutics Inc's price target?
Analysts forecast that Serina Therapeutics Inc's price target is USD 13.00, with the highest forecast at USD 15.00 and the lowest forecast at USD 11.00.
How have Serina Therapeutics IncSER's recent earnings per share performed?
The market expectation was USD -0.58, while Serina Therapeutics IncSER's earnings per share (EPS) for the previous quarter was USD -0.31. EPS for the next quarter is expected at USD -0.46.
What is the analyst rating for Serina Therapeutics Inc?
Based on the ratings of Serina Therapeutics Inc's stock from 2 analysts, most analysts support a STRONG BUY trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as STRONG BUY. Please note that this is not trading advice. You still need to conduct your own analysis.